Compare International Business Machines Corp (IBM) vs Eli Lilly And Co (LLY) Price & Performance

IBM stock trades at $227.44, up 3.14% with recent momentum driven by positive sentiment in the consulting sector following Accenture's strong earnings. The company shows solid fundamentals with 2025 revenue of $67.54B and net income of $10.59B, though technical indicators suggest bearish momentum with the stock trading near resistance at $230. Recent developments include the self-hosted deployment option for IBM Bob AI platform, enhancing enterprise AI sovereignty capabilities.

IBM presents a mixed investment case with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus price target of $255.50 offering 12% upside potential. However, bearish technical signals, recent earnings miss in Q2 2026, and increased investing cash outflows (-$10.3B in 2025) present near-term headwinds. The stock's valuation at 20.13 P/E appears reasonable given the company's hybrid cloud and AI consulting growth trajectory.

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.